1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Dexcom Inc

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.
Kevin Sayer

6340 Sequence Dr
San Diego, California 92121-4356
Phone: 18582000200


Hedge Fund and Insider Trading News: Carlson Capital, SRS Investment Management, Oasis Management, Berkshire Hathway, DexCom, Inc. (DXCM), and More
Feb 26, 2024 18:46pm

Hedge Fund Carlson Shrinks To One Office After Assets Fall 90% (Bloomberg) Hong Kong Investor Files Court Injunction On NEC’s JAE Stake Sale (The Business Times) Fund Manager Explains How To Approach Magnificent 7 Stocks (Investing.com) Ex-Clean Energy Transition Hedge Fund Partner To Launch New Firm (Bloomberg) Positive Performance Seen Across Most Hedge Fund Strategies, […]

Source:Insider Monkey
Xylem, DexCom And 2 Other Stocks Insiders Are Selling
Feb 22, 2024 12:55pm

The Nasdaq 100 closed lower by around 0.4% on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company’s prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga''s insider transactions platform. QuinStreet The Trade: QuinStreet, Inc. (NASDAQ: QNST ) CFO Gregory Wong sold a total of 8,407 shares at an average price of $15.03. The insider received over $126,357 from … Full story available on Benzinga.com

Dexcom Finalizes Stock Warrant Termination and Equity Deals
Feb 15, 2024 21:40pm

Dexcom (DXCM) has released an update. DexCom, Inc. has finalized an agreement with Bank of America to terminate existing warrants for the purchase …

DexCom: A Wealth Compounder In Healthcare
Feb 14, 2024 05:14am

No summary available.

Source:Seeking Alpha
A New Cause for Concern: Dexcom Adds a New Natural and Human Disruptions Risk
Feb 10, 2024 06:00am

Dexcom (DXCM) has disclosed a new risk, in the Natural and Human Disruptions category. Dexcom faces significant business risk from public health cr…

Earnings call: Dexcom reports robust growth and plans for expansion
Feb 09, 2024 14:20pm


Continuous Glucose Monitor Maker Dexcom''s Q4 Profit Triples On Volume Growth And New Customer Additions
Feb 09, 2024 14:17pm

Thursday, after-hours Dexcom Inc (NASDAQ: DXCM ) reported fourth-quarter 2023 earnings with sales of $1.03 billion, up 27% Y/Y (+26% on an organic basis), almost in line with the consensus estimate of $1.02 billion . Volume growth, in conjunction with strong new customer additions, continues to be the primary driver of revenue growth as awareness of real-time continuous glucose monitoring increases. The continuous glucose monitor maker posted profits of $256.3 million, almost triple the $91.8 million a year ago . Adjusted EPS reached $0.50, beating the consensus of $0.43 and up from $0.34 a year ago. Adjusted gross profit totaled $663.8 million or a margin of 64.2% compared to $543.7 million or 66.7% a year ago. Adjusted operating income reached $242.7 million, compared to non-GAAP operating income of $172.1 million for the … Full story available on Benzinga.com

DexCom, Inc. (DXCM) Q4 2023 Earnings Call Transcript
Feb 09, 2024 02:00am

No summary available.

Source:Seeking Alpha
DexCom (DXCM) Q4 2023 Earnings Call Transcript
Feb 09, 2024 00:45am

DXCM earnings call for the period ending December 31, 2023.

Source:The Motley Fool
DexCom, Inc. 2023 Q4 - Results - Earnings Call Presentation
Feb 08, 2024 21:45pm

No summary available.

Source:Seeking Alpha